PSA and prostate cancer: role of the test

The PSA (prostate-specific antigen) is a useful blood marker for early detection of prostate abnormalities; its interpretation requires clinical analysis and further examinations.

MedCluster.ORG

Fewer doubts.
More clarity.

2 emails per month

Clear explanations, practical tips and selected articles to help you better understand your health in everyday life.

How about taking a moment for yourself?

The diagnosis of cancer at an early stage is often difficult. In this case, it is impossible to effectively monitor the symptoms of the disease; frequently, the patient feels no discomfort or attributes their signs to trivial causes. Early-stage prostate cancer can easily be confused with much less serious conditions.

To clarify the diagnosis, the prostate-specific antigen (PSA) is used, a useful marker in oncology. The PSA test is essential in the evaluation of prostate cancer.

Purpose of the test

Several methods are used for diagnosing prostate conditions:

  • prostate ultrasound;
  • clinical examination by digital rectal exam;
  • blood test to measure the concentration of the antigen.

It is this last test that allows for the detection of cancer at an early stage and prevents the progression of the disease. PSA is a protein secreted to liquefy seminal fluid. It is always present in a man’s blood, but its concentration increases significantly in the case of prostate involvement. If the normal value is considered to be ≤ 4 ng/ml, and according to some experts ≤ 3 ng/ml, prostate problems often lead to higher values.

This elevation is explained by increased permeability of prostate tissues, facilitating the passage of PSA into the blood and leading to a rapid exceedance of the reference threshold. Isolated PSA is often the first indicator suggesting an anomaly. At an early stage, the patient may be asymptomatic; a value between 4 and 10 ng/ml justifies further in-depth explorations.

What does a high PSA concentration mean?

A high PSA value in serum does not systematically indicate cancer. It may be due to prostate trauma, prostatitis (inflammation), or benign prostatic hyperplasia (adenoma). In any case, an elevation necessitates a thorough assessment to determine the cause.

The PSA test is not used solely for screening: after treatment, including prostatectomy, periodic blood samples are taken to monitor PSA concentration. After complete removal of the prostate, the expected value is close to zero; a resurgence of PSA growth may indicate the persistence or recurrence of pathological prostate tissue.

Differential diagnosis

PSA exists in serum in bound form (complexed to proteins) and in free form. This distinction is useful in differential diagnosis: a high proportion of free PSA is more frequently observed in benign adenomas, while a higher proportion of bound PSA is often associated with cancer. The analysis of ratios and rates of PSA elevation over time is thus used to refine interpretation.

However, it can happen that PSA remains stable despite the presence of cancer: some tumors lose the ability to secrete the antigen. This is why one should not limit oneself to the biological test alone, and periodic clinical and imaging examinations should be performed.

Normal evolution of PSA with age

The normal value of PSA gradually increases with age:

  • for men aged 40 to 50: about 2.5 ng/ml;
  • for those aged 50 to 60: about 3.5 ng/ml;
  • for those aged 60 to 70: about 4.5 ng/ml;
  • after 70: the value can reach 6.5 ng/ml.

These age-related variations explain why an isolated value should not trigger panic: it is an indicator that must be interpreted by an experienced clinician. It is this clinician who will assess the need for further examinations and the degree of urgency.

Statistically, the relative risk of cancer increases in men aged 40 to 50 when values around 4.5 ng/ml are observed; in this case, further assessment is recommended. Confirmation tests generally include prostate biopsy and multiparametric MRI of the prostate.

James Richardson
Consultant Radiologist
james.richardson@medcluster.org
Contact the author

Receive our next selection of articles

MedCluster.ORG

Understand your health better.
Make informed choices.

2 emails per month

A symptom you want to understand, a common belief to check or a question to ask your doctor: receive our selection of articles for a clearer understanding of your everyday health.

Frequently Asked Questions

What is PSA and what is its significance in prostate cancer?
PSA is a protein secreted by the prostate, measurable in the blood. Its significance lies in its ability to signal silent prostatic abnormalities, including enlargement, inflammation, or cancer. An elevation warrants further assessment to determine the exact origin and guide clinical management.
Does a high PSA value necessarily mean cancer?
No, an increase in PSA does not systematically indicate cancer. Benign causes such as prostatitis, recent prostate trauma, or benign hyperplasia can elevate PSA. Therefore, any high value should lead to further investigations before a definitive diagnosis.
What are the usual PSA thresholds and how do they account for age?
The traditional threshold is set at ≤ 4 ng/ml, with some experts suggesting 3 ng/ml as a caution. Normal values increase with age (≈2.5 ng/ml at 40-50 years, ≈3.5 at 50-60 years, ≈4.5 at 60-70 years, and ≈6.5 after 70 years). Interpretation must consider age and clinical context.
What do the free fraction and the bound fraction of PSA represent?
PSA exists in free and bound forms; the percentage of free PSA relative to total PSA aids in differential diagnosis: a high proportion of free PSA is more often observed in benign adenomas, while an increased share of bound PSA is more suspicious of cancer, guiding the decision for biopsy.
What examinations complement the PSA test in case of elevation?
In case of high PSA, complementary examinations generally include multiparametric MRI of the prostate to target suspicious areas, followed by targeted prostate biopsy if the MRI or clinical context justifies it. A urology consultation is essential to define the diagnostic strategy.
What is the role of PSA after prostate cancer treatment?
After total prostatectomy, PSA should become undetectable; a resurgence of PSA indicates possible persistence or tumor recurrence and necessitates prompt investigations. During other treatments, regular PSA monitoring allows for evaluating therapeutic effectiveness and anticipating potential progression.
What factors can skew the PSA test result?
Several factors influence PSA: recent manipulation of the prostate (biopsy, digital rectal exam), recent sexual activity, urinary infections, urological procedures, certain medications, and inflammation. It is recommended to inform the prescriber of these factors before the sample is taken to avoid misinterpretations.
Should the test be repeated if the PSA is abnormal?
Yes, it is common to repeat the test to confirm an elevation and calculate the PSA velocity. Biological variations exist; repetition helps avoid hasty decisions and guides the need for MRI or biopsy based on the evolution.
At what age and under what conditions should PSA screening begin?
Recommendations vary: systematic screening is not universally recommended, but tests may be offered starting at age 50, or even 45 for those at increased risk (family history, high-risk ethnic background). The decision should be shared between the patient and the physician, considering the benefits and limitations of screening.